Colevas A D
Head and Neck Oncology Program, Dana-Farber/Partners Cancer Care, Boston, Massachusetts, USA.
Oncology (Williston Park). 1997 Sep;11(9 Suppl 10):86-9.
Squamous cell carcinoma of the head and neck is a potentially curable neoplasm. Historically, the standard approach to treatment has been either surgery or radiation therapy, or a combination of the two. Over the past two decades, the role of chemotherapy in the curative approach to head and neck cancer has been evolving. Drugs like fluorouracil (5-FU), cisplatin (Platinol), methotrexate, paclitaxel (Taxol), docetaxel (Taxotere), and bleomycin (Blenoxane) have been investigated in both the palliative and curative settings. Multiple combination regimens have been used as neoadjuvant or induction regimens, but to date the original combination of cisplatin and fluorouracil is still the standard of therapy. UFT, a combination of uracil and tegafur (a fluorinated pyridine analogue), has been available in Japan as an oral form of treatment for squamous cell head and neck cancers. This article describes the rationale behind the use of UFT as an agent for the treatment of squamous cell carcinoma of the head and neck as well as data from ongoing investigations exploring its use in this disease.
头颈部鳞状细胞癌是一种有可能治愈的肿瘤。从历史上看，标准的治疗方法一直是手术或放射治疗，或两者结合。在过去二十年中，化疗在头颈部癌的治愈性治疗中的作用一直在演变。氟尿嘧啶（5-FU）、顺铂（铂尔定）、甲氨蝶呤、紫杉醇（泰素）、多西他赛（泰索帝）和博来霉素（争光霉素）等药物已在姑息治疗和治愈性治疗中进行了研究。多种联合方案已被用作新辅助或诱导方案，但迄今为止，顺铂和氟尿嘧啶的原始联合方案仍是治疗标准。优福定（UFT），即尿嘧啶和替加氟（一种氟化吡啶类似物）的组合，在日本已作为头颈部鳞状细胞癌的口服治疗药物上市。本文描述了使用优福定作为治疗头颈部鳞状细胞癌药物的基本原理，以及正在进行的探索其在该疾病中应用的研究数据。
